IOL Chemicals & Pharmaceuticals Limited has announced that its 39th Annual General Meeting (AGM) will be held on Wednesday, September 2, 2026, at 11:30 a.m. (IST). The meeting is scheduled to transact the business outlined in the accompanying notice, with participation restricted to Video Conferencing ("VC") or Other Audio Visual Means ("OAVM"). This virtual format ensures accessibility for all members while adhering to regulatory guidelines issued by the Ministry of Corporate Affairs (MCA).

The decision to hold the AGM virtually aligns with General Circular No. 03/2025 dated September 22, 2025, and other relevant MCA circulars, which permit the conduct of general meetings without physical presence. The company has also complied with Regulations 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by publishing newspaper advertisements in The Financial Express and Punjabi Jagran on August 2, 2026. The VC/OAVM facility for the meeting will be provided by Central Depository Services Limited (CDSL).

Participation and Documentation

Members can attend and participate in the AGM solely through the VC/OAVM facility. Detailed instructions for joining the meeting will be included in the formal Notice of AGM. Members attending via these digital channels will be counted toward the quorum as per Section 103 of the Companies Act, 2013. Additionally, a live webcast of the proceedings will be available through CDSL’s platform.

The Notice of AGM and the Integrated Annual Report for FY26 will be dispatched electronically to members who have registered their email addresses with the company or their Depository Participants. Physical copies will only be sent upon specific request to investor@iolcp.com , citing the Folio No., DP ID, and Client ID. These documents are also accessible on the company’s website, www.iolcp.com , and the stock exchange websites.

Shareholder Compliance Requirements

To ensure seamless receipt of communications and dividends, shareholders are urged to update their KYC details. The following procedures apply based on the mode of shareholding:

Physical mode holders must send hard copies of Form ISR-1 (as per SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/655), a cancelled cheque bearing the holder's name, self-attested PAN cards, and address proof to Alankit Assignment Limited at 4E/2, Jhandewalan Extension, New Delhi. If the cheque lacks the holder's name, a bank-attested passbook page must also be submitted.

Contact and Support

For assistance related to KYC updates or meeting participation, members may contact the Registrar and Share Transfer Agent, Alankit Assignment Limited, via email at rtat@alankit.com or by telephone at +91-11-4254 1234 / +91-11-4254 1958. The company emphasizes that unregistered email addresses or outdated bank mandates may hinder the electronic delivery of future correspondence and dividend payments.

IOL Chemicals & Pharmaceuticals has received approval from the National Medical Products Administration (NMPA), China, for its Clopidogrel Bisulfate Active Pharmaceutical Ingredient (API). The Centre for Drug Evaluation (CDE) of the NMPA granted this approval on July 14, 2026. This regulatory clearance enables the company to expand its market access in China, adding to its existing valid Certificate of Suitability (CEP) for the same product.

Regulatory Approval Details

The approval from China's NMPA pertains to Clopidogrel Bisulfate, a widely used API in the formulation of antiplatelet medications. The following table summarizes the key details of this development:

Significance of the Approval

Securing NMPA approval is a rigorous process that requires compliance with China's stringent pharmaceutical manufacturing and quality standards. This clearance allows IOL Chemicals & Pharmaceuticals to market and supply Clopidogrel Bisulfate API to pharmaceutical manufacturers operating within China. The development highlights the company's capability to meet international regulatory requirements across key global markets.